Paradigm Capital Management Inc. NY increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares […]
Paradigm Capital Management Inc. NY grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,000 shares of the biopharmaceutical company’s stock after buying an additional 40,000 shares during the quarter. […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) General Counsel Philip C. Strassburger sold 6,831 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total transaction of $33,813.45. Following the transaction, the general counsel now directly owns 109,218 […]
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Ocular Therapeutix in a report on Wednesday, October 4th. View […]